Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2002
10/31/2002US20020161033 Substituted 1,5-dihydropyrrol-2-one derivatives active as NMDA receptor antagonists for treatment of states of pain
10/31/2002US20020161032 Dosage form of a statin and microparticles of fenofibrate stabilized by a phospholipid surface active substrance; bioavailability unaffected by food intake
10/31/2002US20020161030 Sulpur derivatives containing a retroamide bond as inhibitors of endothelin-converting enzymes
10/31/2002US20020161029 Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
10/31/2002US20020161027 2-Methylheptylisonicotinate and process for production thereof
10/31/2002US20020161026 Combination therapies for the stimulation of bone growth
10/31/2002US20020161025 N-substituted indole-3glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action
10/31/2002US20020161024 Administering 2-(piperidin-2,6-dion-3-yl),4-amino-isoindolin-1-one to treat an eye condition
10/31/2002US20020161023 Administering 2-(piperidin-2,6-dion-3-yl),4-amino-isoindolin-1,3-dione to treat an eye condition
10/31/2002US20020161022 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis
10/31/2002US20020161020 Stablization of quinapril using magnesium oxide
10/31/2002US20020161019 For treatment of depression, anxiety, feeding disorders, headache, drug addiction, inflammatory disorders
10/31/2002US20020161018 Enhancement of the potency and efficacy of local anesthetics with ibutilide and other methanesulfonamide drugs
10/31/2002US20020161017 For amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to mammal
10/31/2002US20020161016 As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation
10/31/2002US20020161015 Acylurea containing quinazoline derivatives
10/31/2002US20020161014 Purinyl substituted quinazoline-4-one derivatives
10/31/2002US20020161013 Method of local anesthesia and analgesia
10/31/2002US20020161010 Treatment of various disorders associated with enhanced activity of kinase p38-alpha and/or transforming growth factor beta; antiinflammatory agents
10/31/2002US20020161009 Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction
10/31/2002US20020161008 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression
10/31/2002US20020161006 1,4-dihydropyridine compounds as bradykinin antagonists
10/31/2002US20020161004 Antiinflammation agents
10/31/2002US20020161003 Method and compositions for the eradication and control of methicillin-resistant staphylococcus aureus bacteria and the prevention of the development of antibiotic drug resistance in said bacteria
10/31/2002US20020161002 Use of catecholamine reuptake inhibitors to enhance memory
10/31/2002US20020161001 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV
10/31/2002US20020161000 Treating diseases resulting from tissue breakdown such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, atherosclerosis, and osteoporosis
10/31/2002US20020160999 Treatment of diseases or disorders of the central nervous system
10/31/2002US20020160997 Novel indole derivatives
10/31/2002US20020160995 Suspended in a carrier host agent
10/31/2002US20020160993 Method for treating glaucoma IC
10/31/2002US20020160992 Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
10/31/2002US20020160991 Orally-bioavailable formulations of fentanyl and congeners thereof
10/31/2002US20020160990 Esters with a polyunsaturated fatty acid, for example, eicosapentaenoic acid, beta-sitosterol ester; lowering serum cholesterol levels
10/31/2002US20020160989 Use of delta5-androstene-3beta ol-7,17-dione in the treatment of lupus erythematosus
10/31/2002US20020160988 Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
10/31/2002US20020160987 Novel 4-dedimethylaminotetracycline derivatives
10/31/2002US20020160985 Prevention of infarction by administering an angiotensin II receptor antagonist such as (E)-3-(2-n-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazol-5-yl)-2-n-butyl-2 -propenoic acid
10/31/2002US20020160984 For example, 2,3-dihydro-1H-benz(de)isoquinolin-1-one; treating diabetes, cancer, radiosensitizing tumor cells, cardiovascular disorders, septic shock, inflammatory bowel disease, senescent cells
10/31/2002US20020160983 Substituted benzopyranones as telomerase inhibitors
10/31/2002US20020160982 Modafinil compound and cyclodextrin mixtures
10/31/2002US20020160981 For treatment or prophylaxis of thromboembolic diseases in a mammal having had transluminal angioplasty, synthetic oligosaccharide selective inhibitor of factor Xa acting via antithrombin III and aspirin
10/31/2002US20020160980 Method of treating hepatitis delta virus infection
10/31/2002US20020160979 Methods for inhibiting angiogenesis
10/31/2002US20020160978 Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation
10/31/2002US20020160973 Use of combretastatin A4 and its prodrugs as an immune enhancing therapy
10/31/2002US20020160969 Nucleosides and oligonucleotides containing boron clusters
10/31/2002US20020160968 Inhibitor of niacinamide phosphoribosyl transferase (NAPRT)
10/31/2002US20020160967 Sesame oil, medium-chain triglycerides, glycol esters or fatty acid esters and a cosolvent selected from polyhydric alcohols, cyclic carbonates, acetates, acetals, ketals, or castor oil
10/31/2002US20020160965 Cosmetic and dermatological formulations comprising flavonoids
10/31/2002US20020160964 Conjugates comprising galactose alpha 1,3 galactosyl epitopes and methods of using same
10/31/2002US20020160963 Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists
10/31/2002US20020160962 Non-structural protein 3 (NS3), part of a hepatitis C virus protease necessary for polypeptide processing and viral replication; alpha-ketoamide compounds of given formula
10/31/2002US20020160947 Synergistic method for prolonging allograft survival
10/31/2002US20020160943 Tumor-activated prodrug compounds and treatment
10/31/2002US20020160940 Modulation of endogenous gene expression in cells
10/31/2002US20020160935 Use of leptin antagonists for the treatment of diabetes
10/31/2002US20020160932 Enzyme complex; treatment and prophylaxis of herpes infections; sulfonamide compounds of given formula
10/31/2002US20020160415 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer and for the prevention of cancer in at- risk subjects
10/31/2002US20020160383 Use of nucleic acid analogues in diagnostics and analytical procedures
10/31/2002US20020160379 Gapped 2' modified oligonucleotides
10/31/2002US20020160109 Microencapsulation of drugs by solvent exchange
10/31/2002US20020160082 Protective action on liver function against exogenous and endogenous hepatotoxic agents
10/31/2002US20020160055 Methods for treating human immunodeficiency virus infections with gallium compositions
10/31/2002US20020160050 Comprising one or more hydrophilic cellulose ether polymers, a hydrophilic melt binder, and a therapeutically active ingredient
10/31/2002US20020160048 Medical formulation containing a muscarinic agonist
10/31/2002US20020160047 Use of polyalkylamine polymers in controlled release devices
10/31/2002US20020160046 Delivery system for omeprazole and its salts
10/31/2002US20020160045 Therapeutic dosage form for delivering oxybutynin
10/31/2002US20020160044 Liver selective drug therapy
10/31/2002US20020160043 Dissolvable drug-containing dosage form for use in transmucosal delivery of drug to patient, comprising binding agent formed into solid matrix dissolvable in mouth, pharmacologically effective dosage of drug, buffer
10/31/2002US20020160029 Stable hydroalcoholic compositions
10/31/2002US20020160027 Conjugate, its preparation and use
10/31/2002US20020160019 Providing peptide that bears a DR motif corresponding to a Class II HLA molecule, testing peptide for binding affinity to a Class II HLA DR molecule, whereupon an IC50 binding affinity is determined
10/31/2002US20020160016 Modified surface antigen
10/31/2002US20020160001 That accompanies subarachnoid hemorrhage comprising administering as treatment or prevention an agent that inhibits vascular cell proliferation
10/31/2002US20020159983 Bioprosthetic heart valves
10/31/2002US20020159974 Administering to the patient at least one statin (HMG-Coa-reductase inhibitor) in an amount effective to modulate MHC class II (Major Histocompability complex) or CD/40(antigen) expression in the patient
10/31/2002US20020159973 Administering to the patient at least one statin (HMG-Coa-reductase inhibitor) in an amount effective to modulate MHC class II (Major Histocompability complex) or CD/40(antigen) expression in the patient
10/31/2002US20020159968 A stable polyallylamine hydrochloride polymer crosslinked by epichlorohydrin
10/31/2002US20020159951 Administering to the patient a contrast agent comprising, in an aqueous carrier, targeted vesicles formulated from a lipid or polymer, a prfluorocarbon gas, a targeting ligand, scanning the patient using ultrasound to obtain an image
10/31/2002US20020158255 Compounds of the general formula P1-L-P2; wherein "P1" is a pyrazinoylguanidine sodium channel blocker, "L" is a linking group, and "P2" is either (i) a pyrazinoylguanidine sodium channel blocker or (ii) a P2Y2 receptor agonist, are disclosed
10/31/2002US20020158226 Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
10/31/2002US20020157675 Compositions and medical procedure to treat snoring
10/31/2002EP1232171A4 Method of preparing clarithromycin
10/31/2002DE10217066A1 Composition useful for treatment of central nervous system disorders, e.g. Alzheimer's disease comprises modulator of neuron-specific calcium sensor-1
10/31/2002DE10204634A1 Composition useful as a food or food supplement, and for treating e.g. tumors or osteoporosis, contains isoflavone, lignan and phytosterol
10/31/2002DE10140653A1 Detecting stress-relieving activity of test compounds, by subjecting human test subject to physical stress followed by stress relief while monitoring by electro-physiological methods and/or body fluid analysis
10/31/2002DE10121217A1 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden 6H-oxazolo [4,5-e] indole derivatives as nicotinic acetylcholine receptor ligands and / or serotonergic ligands
10/31/2002DE10121215A1 Dihydro-imidazo[4,5-e]indol- und 7H-Pyrrolo[3,2-f]chinoxalin Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden Dihydro-imidazo [4,5-e] indole and 7H-pyrrolo [3,2-f] quinoxaline derivatives as nicotinic acetylcholine receptor ligands and / or serotonergic ligands
10/31/2002DE10121090A1 New cosmetic or dermatological compositions comprise a synergistic combination of sericoside and tetrahydrocurcumin or its derivatives, useful for treating e.g. skin inflammation and aging symptoms
10/31/2002DE10120627A1 Verwendung von Phyllanthusbestandteilen zur Behandlung oder Prophylaxe von Infekten durch Hepatitis B-Viren Use of Phyllanthus for the treatment or prophylaxis of infections caused by hepatitis B viruses
10/31/2002DE10120605A1 Behandlung von Retina- oder Photorezeptor-Degenerationserkrankungen Treatment of retinal photoreceptor degeneration or disease
10/31/2002DE10120159A1 NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen NMDA antagonists and NMDA agonists for the treatment of addictions
10/31/2002DE10118452A1 Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse Nucleic acid sequences of hyperplasias and tumors of the thyroid
10/31/2002CA2791888A1 Proliposomal drug delivery system
10/31/2002CA2483507A1 Enzyme and snp marker for disease
10/31/2002CA2449415A1 Intraoral delivery of nicotine for smoking cessation
10/31/2002CA2445888A1 Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions
10/31/2002CA2445508A1 Agent for topical ophthalmic treatment of ocular inflammatory diseases
1 ... 5664 5665 5666 5667 5668 5669 5670 5671 5672 5673 5674 5675 5676 5677 5678 5679 5680 5681 5682 5683 5684 ... 7860